What Pharmacists Need to Know as Ebola Cases Climb in the Democratic Republic of the Congo and Uganda

This FAQ was fact-checked by Jacinda Abdul-Mutakabbir (JAM), PharmD, MPH.

An outbreak of Ebola disease caused by Bundibugyo ebolavirus, one of several ebolavirus species that can cause disease in humans, is continuing to expand in the Democratic Republic of the Congo (DRC) and Uganda, prompting the WHO to declare a public health emergency of international concern. Although no cases have been confirmed in the United States, the outbreak's severity and the global attention it has drawn mean patients are likely to have questions. This FAQ reviews the current outbreak status, the unique challenges posed by this particular Ebola species, and the pharmacist's role in patient education and risk communication.

Q1: What is the current status of the Ebola outbreak, and where is it occurring?

The outbreak, which is the second largest Ebola outbreak on record, began in early May 2026, when a hospital in Bunia Health Zone in Ituri Province, northeastern DRC, identified a cluster of severe illness among health care workers. Genetic testing identified the cause as Bundibugyo ebolavirus, 1 of 4 orthoebolavirus species known to cause Ebola disease in humans.

As of June 22, the DRC Ministry of Health has confirmed more than 1000 cases and 256 confirmed deaths, with the outbreak now affecting 31 health zones across 3 provinces—Ituri, Nord-Kivu, and Sud-Kivu. Uganda has reported a separate but linked cluster tied to cross-border travel from DRC, with 19 confirmed cases. The WHO declared the outbreak a public health emergency of international concern on May 17, 2026, and the case-fatality ratio has been estimated around 24%, consistent with the 33% to 55% range historically associated with Bundibugyo ebolavirus outbreaks.

Q2: Why is this outbreak considered especially difficult to control?

Several factors are complicating the response. The outbreak is occurring in a region affected by population displacement as well as active mining and trade corridors, all of which increase the risk of further spread and complicate contact tracing and treatment delivery. Critically, Bundibugyo ebolavirus is genetically distinct from Zaire ebolavirus, the species responsible for most prior major outbreaks (including the 2014–2016 epidemic in West Africa) and the species for which existing vaccines and monoclonal antibody treatments were developed.

As a result, there is currently no approved vaccine or antiviral treatment specific to Bundibugyo ebolavirus, and care for affected patients relies primarily on supportive measures such as fluid and electrolyte management. Several vaccine candidates and therapeutics, including remdesivir (Veklury; Gilead Sciences), the monoclonal antibody combination MBP-134 (Mapp Biopharmaceutical, Inc.), and maftivimab (Inmazeb; Regeneron Pharmaceuticals), are being fast-tracked into clinical trials, but none have yet been validated for this outbreak.

Q3: What is the risk to people in the United States?

According to the Centers for Disease Control and Prevention (CDC) formal risk assessment, the risk to the general American public remains low. To date, there have been no confirmed cases in the US. The CDC has implemented enhanced public health screening for travelers arriving from the affected countries at several US airports and has issued travel health notices:

• a Level 3 notice (reconsider nonessential travel) for DRC;
• and a Level 1 notice (practice usual precautions) for Uganda.

Two American health care workers who were exposed while treating patients in DRC were medically evacuated to facilities in Europe for monitoring and care, of whom 1 developed Ebola disease and recovered following treatment. This emphasizes both the seriousness of exposure risk for health care workers and the value of rapid isolation and specialized care.

Q4: What should pharmacists know about Ebola transmission and symptoms to respond appropriately?

Ebola disease spreads through direct contact with the blood, bodily fluids, or secretions of an infected symptomatic person, or with contaminated surfaces and materials. It is not airborne. Early symptoms, which are nonspecific and can resemble many common illnesses, include the following:

• fever
• severe headache
• muscle pain
• weakness
• fatigue

More severe cases can experience:

• vomiting
• diarrhea
• abdominal pain
• unexplained bleeding or bruising

Because of this overlap with more common conditions, pharmacists should maintain a low threshold of suspicion only in patients who report both compatible symptoms and a relevant exposure history, such as recent travel to an affected area or contact with a confirmed case. Pharmacists who encounter a patient meeting both criteria should avoid direct contact with bodily fluids, instruct the patient to seek immediate medical evaluation at a facility that is prepared for isolation, and notify their local or state health department promptly, since Ebola is a nationally notifiable condition.

Q5: How can pharmacists counsel patients who are anxious about the outbreak?

Pharmacists are well positioned to provide calm, accurate context for patients who may be alarmed by outbreak headlines. The most important message is also the simplest: for the general public in the US who have neither traveled to the affected region nor had contact with a confirmed case, individual risk is extremely low, and no specific precautions are currently recommended.

For patients with upcoming travel to DRC or Uganda, pharmacists can point them toward CDC's destination-specific travel health notices and encourage a pretravel health consultation, since recommendations may evolve as the outbreak develops. It is also worth gently correcting common misconceptions: Ebola is not spread through casual contact, air, water, or food, and a person is not contagious until they develop symptoms. For patients who are simply seeking reassurance, validating their concern while grounding the conversation in current risk data, rather than dismissing the question outright, tends to be the most effective approach and helps preserve trust for future health conversations.

Q6: Where can pharmacists find reliable, up-to-date information on this outbreak?

Because outbreak data is changing rapidly, pharmacists should rely on primary sources rather than secondhand media coverage. CDC's Ebola “Current Situation” page and its Health Alert Network advisories provide US-specific guidance and travel notices. The WHO's Disease Outbreak News page and its Africa regional office situation reports offer the most current confirmed case and fatality figures from DRC and Uganda. Pharmacists should check these sources directly before counseling patients, given how quickly the figures have moved week to week since the outbreak began.

Summary for Practice

While the 2026 Bundibugyo ebolavirus outbreak in DRC and Uganda remains a serious and evolving public health emergency, the risk to the US public continues to be assessed as low. Pharmacists can play a meaningful role by understanding the basics of transmission and symptoms, knowing when exposure history warrants referral to the health department, and offering patients calm, evidence-based reassurance grounded in current risk data rather than outbreak headlines.